Medplus Health's subsidiary, Optival Health Solutions, received a 5-day suspension of its drug license at a Hanamkonda store due to regulatory violations. The financial impact is negligible.
Catalyst Trusteeship Limited reported the creation of a pledge over 49,00,000 equity shares of Medplus Health Services Limited. This disclosure pertains to debenture trustee arrangements.
Medplus Health Services' subsidiary, Optival Health Solutions, received a two-day drug license suspension for a Karnataka store. The financial impact is estimated at ₹0.0029 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, received regulatory orders suspending drug licenses for three stores for two days due to compliance violations.
MedPlus Health Services' subsidiary, Optival Health, received two-day drug license suspensions for three stores. The total estimated potential revenue loss is ₹0.024 Crore.
MedPlus Health Services Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI Listing Regulations.
Medplus reported strong revenue growth but faced significant margin pressure from a lower private label mix and rising employee costs due to regulatory changes.
MedPlus approved Rs 130 Crore capex for a food park and wellness facility, plus unaudited quarterly results and the appointment of a new Company Secretary.
Medplus Health Services' subsidiary, Optival Health, faces a two-day drug license suspension at a Karnataka store. Financial impact is estimated at a negligible ₹0.0053 Crore.
MedPlus subsidiary Optival Health Solutions faces a 2-day drug license suspension at a Karnataka store, with a potential revenue loss of ₹0.0053 Crore.
MedPlus subsidiary Optival Health Solutions faced one to two-day drug license suspensions across three Karnataka stores. The estimated total revenue impact is approximately Rs. 1.59 lakhs.